5 results match your criteria: "Instituto de Investigación Sanitaria Hospital Puerta de Hierro-Segovia de Arana[Affiliation]"
Factors related to the development of high antibody titres against SARS-CoV-2 in convalescent plasma donors from the ConPlas-19 trial.
Vox Sang
January 2024
Department of Hematology, Hospital Universitario Puerta de Hierro Majadahonda, Instituto de Investigación Sanitaria Hospital Puerta de Hierro-Segovia de Arana, Madrid, Spain.
Background And Objectives: The efficacy of COVID-19 convalescent plasma (CP) associates with high titres of antibodies. ConPlas-19 clinical trial showed that CP reduces the risk of progression to severe COVID-19 at 28 days. Here, we aim to study ConPlas-19 donors and characteristics that associate with high anti-SARS-CoV-2 antibody levels.
View Article and Find Full Text PDFLonger intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concern.
J Med Virol
March 2023
AIDS Immunopathogenesis Unit, Instituto de Salud Carlos III, Madrid, Spain.
Article Synopsis
- The study evaluated the immune response to SARS-CoV-2 variants in individuals who had recovered from COVID-19, focusing on two groups based on the time elapsed since infection (1-3 months vs. 4-12 months).
- It found that recovered individuals had higher antibody levels compared to naïve participants after vaccination, especially after receiving their second dose.
- Longer intervals between infection and vaccination (more than 3 months) significantly improved the effectiveness of the immune response against various strains of the virus, highlighting the importance of timing in vaccination strategies.
Pathogen reduction with methylene blue does not have an impact on the clinical effectiveness of COVID-19 convalescent plasma.
Vox Sang
April 2023
Department of Hematology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.
Background And Objectives: There is a concern about a possible deleterious effect of pathogen reduction (PR) with methylene blue (MB) on the function of immunoglobulins of COVID-19 convalescent plasma (CCP). We have evaluated whether MB-treated CCP is associated with a poorer clinical response compared to other inactivation systems at the ConPlas-19 clinical trial.
Materials And Methods: This was an ad hoc sub-study of the ConPlas-19 clinical trial comparing the proportion of patients transfused with MB-treated CCP who had a worsening of respiration versus those treated with amotosalen (AM) or riboflavin (RB).
Molecular Divergence upon -TKI Resistance Could Be Dependent on the Exon Location of the Original -Sensitizing Mutation.
Cancers (Basel)
September 2022
Medical Oncology, Hospital Puerta de Hierro, 28222 Majadahonda, Spain.
Tumor molecular profiling upon disease progression enables investigations of the tumor evolution. Next-generation sequencing (NGS) of liquid biopsies constitutes a noninvasive readily available source of tumor molecular information. In this study, 124 plasma samples from advanced EGFR-positive NSCLC patients, treated with a first-line EGFR tyrosine kinase inhibitor (EGFR-TKI) were collected upon disease progression.
View Article and Find Full Text PDFA multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia.
J Clin Invest
October 2021
Department of Hematology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain.
BACKGROUNDPassive immunotherapy with convalescent plasma (CP) is a potential treatment for COVID-19. Evidence from controlled clinical trials is inconclusive.METHODSWe conducted a randomized, open-label, controlled clinical trial at 27 hospitals in Spain.
View Article and Find Full Text PDF